Evaluation of Multiple Serum Markers in Advanced Melanoma

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2011 Aug 23

PMID 21858537

Citations 24

Authors

Angel Diaz-Lagares

Estibaliz Alegre

Ainhoa Arroyo

Maria Gonzalez-Cao

Maria E Zudaire

Santiago Viteri

Salvador Martin-Algarra

Alvaro Gonzalez

Affiliations

Soon will be listed here.

Abstract

The aim of this retrospective study was to analyse in advanced melanoma the potential tumor markers S-100B, melanoma inhibiting activity protein (MIA) and YKL-40 compared to LDH. Serum levels of S-100B, MIA, LDH and YKL-40 were measured in 110 patients with advanced melanoma (36 in stage IIIB/C and 74 in stage IV), in 66 disease-free patients and in 65 healthy controls. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. The combination of S-100B plus MIA had the best diagnostic sensitivity, and the addition of LDH did not further increase this sensitivity. MIA was an independent prognostic factor of overall survival. Patients with both S-100B and MIA elevated had a significant shorter survival than those with both S-100B and MIA under the cut-off. YKL-40 levels did not differentiate patients with advanced melanoma from controls. We concluded that the combination of MIA plus S-100B showed a better prognostic value in advanced melanoma compared to LDH.

Citing Articles

Exosomal Non-coding RNAs: A New Approach to Melanoma Diagnosis and Therapeutic Strategy.

Liu J, Hu X, Xin W, Wang X Curr Med Chem. 2023; 31(37):6084-6109.

PMID: 37877505 DOI: 10.2174/0109298673267553231017053329.

Correlation Studies between S100 Protein Level and Soluble MIA or Tissue MelanA and gp100 (HMB45) Expression in Cutaneous Melanoma.

Bolovan L, Ceausu M, Stanciu A, Panait M, Busca A, Hotnog C J Pers Med. 2023; 13(6).

PMID: 37373887 PMC: 10305456. DOI: 10.3390/jpm13060898.

Predictive Performance of Serum S100B LDH in Melanoma Patients: A Systematic Review and Meta-Analysis.

Janka E, Varvolgyi T, Sipos Z, Soos A, Hegyi P, Kiss S Front Oncol. 2021; 11:772165.

PMID: 34950582 PMC: 8688362. DOI: 10.3389/fonc.2021.772165.

The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients.

Paolino G, Huber V, Camerini S, Casella M, Macone A, Bertuccini L Cancers (Basel). 2021; 13(16).

PMID: 34439311 PMC: 8392159. DOI: 10.3390/cancers13164157.

uPAR extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients.

Porcelli L, Guida M, De Summa S, Di Fonte R, De Risi I, Garofoli M J Immunother Cancer. 2021; 9(5).

PMID: 33972390 PMC: 8112420. DOI: 10.1136/jitc-2021-002372.

References

Johansen J . Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006; 53(2):172-209. View

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A . Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2009; 46(2):270-83. DOI: 10.1016/j.ejca.2009.10.032. View

Gogas H, Eggermont A, Hauschild A, Hersey P, Mohr P, Schadendorf D . Biomarkers in melanoma. Ann Oncol. 2009; 20 Suppl 6:vi8-13. PMC: 2712589. DOI: 10.1093/annonc/mdp251. View

Harpio R, Einarsson R . S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem. 2004; 37(7):512-8. DOI: 10.1016/j.clinbiochem.2004.05.012. View

Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M . Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int. 2001; 20(5):192-6. DOI: 10.1007/s002960100115. View

Brochez L, Naeyaert J . Serological markers for melanoma. Br J Dermatol. 2000; 143(2):256-68. DOI: 10.1046/j.1365-2133.2000.03649.x. View

Kluger H, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y . Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res. 2011; 17(8):2417-25. PMC: 3415234. DOI: 10.1158/1078-0432.CCR-10-2402. View

Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann R . Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges. 2008; 6 Suppl 1:S9-S14. DOI: 10.1111/j.1610-0387.2008.06711.x. View

Hofmann M, Gussmann F, Fritsche A, Biesold S, Schicke B, Kuchler I . Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res. 2008; 19(1):17-23. DOI: 10.1097/CMR.0b013e32831bc78c. View

10.

Miliotes G, Lyman G, Cruse C, Puleo C, Albertini P, Rapaport D . Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol. 1996; 3(6):558-63. DOI: 10.1007/BF02306089. View

11.

Hsueh E, Gupta R, Glass E, Yee R, Qi K, Morton D . Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg. 1998; 187(2):191-7. DOI: 10.1016/s1072-7515(98)00140-9. View

12.

Egberts F, Pollex A, Egberts J, Kaehler K, Weichenthal M, Hauschild A . Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie. 2008; 31(7):380-4. DOI: 10.1159/000135492. View

13.

Schmidt H, Johansen J, Gehl J, Geertsen P, Fode K, von der Maase H . Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006; 106(5):1130-9. DOI: 10.1002/cncr.21678. View

14.

Kruijff S, Bastiaannet E, Muller Kobold A, van Ginkel R, Suurmeijer A, Hoekstra H . S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol. 2009; 16(12):3455-62. PMC: 2779363. DOI: 10.1245/s10434-009-0629-8. View

15.

Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V . S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999; 17(6):1891-6. DOI: 10.1200/JCO.1999.17.6.1891. View

16.

Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G . Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v194-7. DOI: 10.1093/annonc/mdq188. View

17.

Tarhini A, Stuckert J, Lee S, Sander C, Kirkwood J . Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2008; 27(1):38-44. PMC: 3426933. DOI: 10.1200/JCO.2008.17.1777. View

18.

Johansen J, Jensen B, Roslind A, Price P . Is YKL-40 a new therapeutic target in cancer?. Expert Opin Ther Targets. 2007; 11(2):219-34. DOI: 10.1517/14728222.11.2.219. View

19.

Gonzalez Cao M, Auge J, Molina R, Marti R, Carrera C, Castel T . Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res. 2007; 27(1B):595-9. View

20.

Auge J, Molina R, Filella X, Bosch E, Gonzalez Cao M, Puig S . S-100beta and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res. 2005; 25(3A):1779-82. View